Related Experiment Videos
Erythrocyte P1 group antigen expression in VTEC-associated hemolytic uremic syndrome
A Ashida1, K Matsui, T Chizaki
1Department of Pediatrics, Osaka Medical College, Takatsukishi, Japan.
Insights
The P1 blood group antigen does not protect against hemolytic uremic syndrome (HUS) in Japanese children. This study found no significant difference in P1 antigen presence between children with and without a history of HUS following hemorrhagic colitis.
Area of Science:
- Immunology
- Genetics
- Pediatrics
Background:
- The P1 blood group antigen's potential protective role against verotoxin-associated hemolytic uremic syndrome (HUS) has been theorized.
- Hemolytic uremic syndrome (HUS) is a serious complication often following infections like hemorrhagic colitis (HC).
Purpose of the Study:
- To investigate whether the P1 blood group antigen acts as a protective factor against the development of HUS in Japanese children.
- To determine the frequency of the P1 phenotype in children with and without a history of postdiarrheal HUS.
Main Methods:
- A cohort of 59 Japanese children with a history of hemorrhagic colitis (HC) was studied.
- The P1 blood group antigen was detected using a direct agglutination method with a commercial anti-P1 antibody.
Main Results:
- The P1 antigen was present in 21.1% of patients with a history of HUS and 28.0% of those without.
- No statistically significant difference was observed in the frequency of the P1 phenotype between the two groups (p = 0.629).
Conclusions:
- The P1 blood group antigen is not a protective factor against HUS development in Japanese individuals.
- Verotoxin-producing Escherichia coli (VTEC)-induced HUS following HC is not influenced by the P1 blood group antigen in this population.
Background:
The P1 blood group antigen has been postulated as a protective host factor against the development of the verotoxin-associated with hemolytic uremic syndrome (HUS).
Patients And Methods:
In this study the P1 blood group antigen in 59 Japanese children with a past history of hemorrhagic colitis (HC) was scored with a direct agglutination method using a commercial anti P1 antibody.
Results:
The P1 antigen was positive in 4 (21.1%) of 19 patients with a history of postdiarrheal HUS and in 11 (28.0%) of 40 patients with no history. There were no significant differences in the frequency of the P1 phenotype between the 2 groups (p = 0.629).
Conclusion:
We concluded that the P1 blood group antigen is not a protective factor against the development of HUS from verotoxin-producing Escherichia coli(VTEC)-infected hemorrhagic colitis in Japanese individuals.